ARRY-470,
larotrectinib,
LOXO-101,
N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide,
Larotrectinib sulfate,
LOXO-101 sulfate,
UNII-RDF76R62ID,
RDF76R62ID,
1223405-08-0,
Larotrectinib (LOXO-101) sulfate,
ARRY-470,
Larotrectinib sulfate (USAN),
Larotrectinib sulfate [USAN],
(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide sulfate,
1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, sulfate (1:1),
1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-, sulfate (1:1),
ARRY-470 sulfate,
LOXO-101(sulfate),
LOXO-101 (sulfate),
SCHEMBL2239598,
CHEMBL3989939,
PXHANKVTFWSDSG-QLOBERJESA-N,
HY-12866A,
s7960,
AKOS030526332,
CS-5314,
D11138,
(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate,
Larotrectinib,
LOXO-101,